Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rang in Aktien #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Aktienkurs
$0.00023723
Zuletzt synchronisiert: 2024-08-26
Marktkapitalisierung
$1.41K
Veränderung (1 Tag)
111.67%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Pharnext S.A. (ALPHA)

Kategorie

Kursverlauf für Pharnext S.A. (ALPHA)
Höchster Schlusskurs: $0.00 am 2024-08-01

Niedrigster Schlusskurs: $2.68M am 2023-06-01
Kursverlauf der Aktie von Pharnext S.A. von 2023 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 -100.00%
2023 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.08K -6.98%
KR